BNC Wealth Management’s Anavex Life Sciences AVXL Stock Holding History

BNC Wealth Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.1K	Hold	11,250	–	–	0.01%	106
2026 Q1	$34.5K	Sell	11,250 -1,000	-8%	-$4.33K	0.01%	106
2025 Q4	$43.6K	Buy	12,250 +2,000	+20%	+$12.3K	0.01%	106
2025 Q3	$91.2K	Hold	10,250	–	–	0.02%	106
2025 Q2	$94.5K	Hold	10,250	–	–	0.03%	97
2025 Q1	$87.9K	Hold	10,250	–	–	0.03%	97
2024 Q4	$110K	Hold	10,250	–	–	0.04%	95
2024 Q3	$58.2K	Hold	10,250	–	–	0.02%	92
2024 Q2	$43.3K	Sell	10,250 -6,850	-40%	-$27.7K	0.02%	99
2024 Q1	$87K	Hold	17,100	–	–	0.04%	101
2023 Q4	$159K	Buy	17,100 +500	+3%	+$3.44K	0.08%	93
2023 Q3	$109K	Buy	16,600 +3,550	+27%	+$28.3K	0.06%	95
2023 Q2	$106K	Hold	13,050	–	–	0.06%	97
2023 Q1	$112K	Buy	+13,050	New	+$130K	0.06%	105
2020 Q4	–	Sell	-5,550	Closed	-$25K	–	124
2020 Q3	$25K	Buy	+5,550	New	+$23.9K	0.02%	203

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNC Wealth Management's AVXL Position: Q2 2026 in Review

BNC Wealth Management held its Anavex Life Sciences (AVXL) position steady in Q2 2026 at 11,250 shares worth $29.1K. The position accounts for 0.01% of the portfolio, ranked #106.

BNC Wealth Management first reported a position in AVXL in Q3 2020 and has held it in 15 quarters since. The position peaked at $159K in Q4 2023. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

BNC Wealth Management held 11,250 shares of Anavex Life Sciences worth $29.1K as of Q2 2026.
BNC Wealth Management left its Anavex Life Sciences share count unchanged in Q2 2026.
Anavex Life Sciences made up 0.01% of BNC Wealth Management's portfolio in Q2 2026, its #106 holding.
BNC Wealth Management first reported a position in Anavex Life Sciences in Q3 2020 and has held it in 15 quarters since.
BNC Wealth Management's Anavex Life Sciences position peaked at $159K in Q4 2023.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on BNC Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.